The present invention relates to compounds of general formula (I) wherein the group (Het)Ar is defined as in claim 1 which have valuable pharmacological properties in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor such as metabolic diseases in particular diabetes type 2.
